Overview

Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study is being done to: - Test the safety of EP-100 and see what effect (good and bad) it has on the patient and their cancer; - Find the highest dose of EP-100 that can be given without causing bad side effects; - Examine how much EP-100 is in the blood at certain times after it is given and how quickly the body gets rid of it; - Observe whether there is any effect of EP-100 on the size and activity of cancer in the patient's body.
Phase:
Phase 1
Details
Lead Sponsor:
Esperance Pharmaceuticals Inc